PCVX
What one share of Vaxcyte holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform.
Vaxcyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$7.65 |
|---|---|
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$6.42 |
| Dividends | $0.00 |
| Cash and investments | $1.27 |
| Book value | $19.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$8.12 | $0.49 | −$8.88 | — | −$15.90 |
| 2019 | — | −$13.25 | $0.31 | −$12.74 | $0.00 | −$26.20 |
| 2020 | — | −$3.02 | $0.04 | −$1.62 | $0.00 | $6.77 |
| 2021 | — | −$1.93 | $0.13 | −$2.46 | $0.00 | $5.36 |
| 2022 | — | −$3.44 | $0.09 | −$2.72 | $0.00 | $12.00 |
| 2023 | — | −$4.14 | $0.17 | −$3.22 | $0.00 | $13.01 |
| 2024 | — | −$3.80 | $0.18 | −$3.89 | $0.00 | $26.47 |
| 2025 | — | −$5.63 | $0.10 | −$4.92 | $0.00 | $20.49 |